Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Imiquimod, Pembrolizumab, Sotigalimab, Synthetic Tumor-Associated Peptide Vaccine Therapy.
- Кому может быть актуально
- Состояния в реестре: Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- США
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma
Обзор
This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing or kill them.
Подробное описание
PRIMARY OBJECTIVES:
I. Demonstrate that developing a custom vaccine for metastatic pancreatic ductal adenocarcinoma (PDA) and colorectal cancer (CRC) patients is feasible. (cohorts A and B)
II. Show that a custom peptide-based vaccine in combination with imiquiomod, pembrolizumab, and/or sotigalimab (APX005M) is safe. (cohorts A and B and C and D)
SECONDARY OBJECTIVES:
I. Determine the clinical benefit of the peptide vaccine alone or combined with pembrolizumab or pembrolizumab and APX005M. (cohorts A and B and C and D)
II. Demonstrate the antigenicity of each vaccine. (cohorts A and B and C and D)
III. The change in neoantigen-specific T cell responses at 12 weeks after initiation of personalized peptide vaccination. (cohorts C and D)
IV. Relapse-free survival and circulating tumor deoxyribonucleic acid (ctDNA) clearance rate. (cohorts C and D)
OUTLINE: Patients are assigned to 1 of 3 cohorts.
COHORT A: Patients receive personalized synthetic tumor-associated peptide vaccine therapy subcutaneously (SC) on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients then receive imiquimod cream topically in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.
COHORT B: Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 12, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab intravenously (IV) over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and at weeks 0 and 6, then every 3 months, and at week 39.
COHORTS C AND D: Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4, 6, 9, 12, 15, 18, 21, and 24. Beginning 15 minutes after each vaccine is administered, patients receive imiquimod cream topically. Patients also receive pembrolizumab IV over 30 minutes every 3 weeks until week 24 in the absence of disease progression or unacceptable toxicity. Beginning about 1 hour after each vaccine, patients also receive sotigalimab IV over 60 minutes on day 1 of weeks 0, 1, 3, 4, 6, 9, 12, 15, 18, 21, and 24 in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans at baseline and weeks 6,12, and 24, then every 3 months, and at week 39.
After completion of study treatment, patients are followed for 6 months.
Вмешательства
- Препарат Imiquimod
Applied topically - Биопрепарат Pembrolizumab
Given IV - Биопрепарат Sotigalimab
Given IV - Биопрепарат Synthetic Tumor-Associated Peptide Vaccine Therapy
Given SC - Процедура Computed Tomography
Undergo CT - Процедура Magnetic Resonance Imaging
Undergo MRI
Первичные конечные точки
- Proportion of enrolled patients for whom a personalized vaccine is developed and ready to administer (cohorts A and B) [Срок оценки: Up to 12 weeks post-enrollment]
- Proportion of enrolled patients who receive at least 1 dose of vaccine at any time post-enrollment (cohorts A and B) [Срок оценки: Up to 44 weeks]
- Incidence of adverse events (AEs) [Срок оценки: Up to 24 weeks]
Вторичные конечные точки (12)
- Proportion of patients who have received at least one dose of vaccine that is alive and progression free defined based on response criteria according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 [Срок оценки: At 12 weeks post-vaccination (second re-staging scan)]
- Progression-free survival (cohorts A and B and C) [Срок оценки: The time between the date of first vaccination and evidence of progression on computed tomography scan or the date of death due to any cause, assessed up to 6 months after the last dose of vaccine]
- Response rate (cohort A and B) [Срок оценки: Up to 12 weeks]
- Change in tumor biomarker (CA19-9, carcinoembryonic antigen [CEA] or circulating free deoxyribonucleic acid [cfDNA] mutation) [Срок оценки: Up to 6 months]
- Overall survival [Срок оценки: The time from first vaccination to death, assessed up to 6 months after the last dose of vaccine]
- Recurrence-free survival (cohort C and D) [Срок оценки: Up to 6 months]
- Rate of circulating deoxyribonucleic acid (ctDNA) clearance (cohort C and D) [Срок оценки: Up to 6 months]
- Change in neoantigen-specific T cell response (cohort C and D) [Срок оценки: Baseline to 12 weeks after initiation of personalized peptide vaccination]
- Correlation of T-cell activation against vaccinated peptides and ctDNA dynamics (cohort C and D) [Срок оценки: Up to 6 months]
- Tumor microenvironment immune infiltration and progression biopsies (cohort C and D) [Срок оценки: Baseline, up to 6 months]
- T cell IFN-gamma release in response to selected personalized peptide antigens [Срок оценки: Up to 6 months]
- Levels of intracellular cytokine staining of T cells [Срок оценки: Up to 6 months]
Критерии участия
Критерии включения
- Metastatic CRC or PDA planned to or have undergone complete surgical resection (metastatectomy) and also for PDA participants with localized disease planned for primary tumor resection.
- Any lines (including zero) of therapy prior to tissue harvest.
- Adequate tumor tissue availability
- Adults (age ≥ 18)
- ECOG PS 0-1
- Life expectancy >12 months for Cohort C and >9 months for Cohort D
- Adequate organ and marrow function
- Ability to understand and the willingness to sign a written informed consent document.
- As the effects of a peptide based vaccine, pembrolizumab or APX005M on the developing human fetus are unknown, women of child-bearing potential and men must agree to use adequate contraception at study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant, she should inform her treating physician immediately. Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), sexually active participants must use birth control during and for >120 days after the study. Abstinence is also an acceptable form of birth control.
- For Cohort C only: participants must have metastatic CRC and are planned to or have undergone complete metastecomy/ies and agree to have post-operative blood draw for ctDNA testing within 6 weeks following surgical resection.
Критерии исключения
- History of HIV or AIDS
- Patients with brain metastasis
- Serious autoimmune conditions
- Use of chronic immune suppressive medications.
- Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Women of child bearing potential who are pregnant or breastfeeding. Women with a positive pregnancy test at enrollment or prior to administration of vaccine. .
- Has history of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis.
- Known history of active TB (Bacillus Tuberculosis).
- Hypersensitivity to therapy drugs or their components.
- Has a known additional malignancy that is progressing or requires active treatment.
- Active coagulopathy.
- History of arterial thrombosis within 3 months prior to starting study treatment.
- History of New York Heart Association Class 3-4 heart failure or myocardial infarction within 6 months prior to starting therapy.
- Known history of Hepatitis B or known active Hepatitis C.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Нерандомизированное
- Модель
- Параллельные группы
- Маскирование
- Открытое
- Основная цель
- Лечение
Центры проведения
США · 1 центр
- M D Anderson Cancer Center — Houston
Идентификаторы
NCT: NCT02600949 · 2014-1029 · NCI-2016-00015 · 2014-1029